May 29, 2020
AstraZeneca with promising results from clinics for Imfinzi and Enhertu
AstraZeneca on Friday reported several clinical results from its studies, including Imfinzi and Enhertu, with meaningful outcomes.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: trastuzumab
May 22, 2020
Enhertu granted orphan drug designation in the US for gastric cancer
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
May 11, 2020
Enhertu designated breakthrough therapy in the U.S. for HER2 gastric cancer
Daiichi Sankyo and AstraZeneca’s Enhertu trastuzumab has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.
May 7, 2020
Canbridge gets marketing approval of Nerlynx in China
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner CANbridge Pharmaceuticals, Inc. has received marketing approval of NERLYNX® (neratinib) in mainland China from the National Medical Products Administration (NMPA) of China.
June 24, 2019
Global Cancer Monoclonal Antibodies Market Outlook 2019-2024 – Trastuzumab (Herceptin) Expected to Hold a Significant Market Share
DUBLIN–(BUSINESS WIRE)–The “Cancer Monoclonal Antibodies Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s…
March 12, 2019
Pfizer’s Trazimera, cancer biosimilar to Genentech Inc’s Herceptin, approved in USA
Pfizer got approval for Trazimera n USA for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 adenocarcinoma.